Xencor, Inc. NASDAQ:XNCR

Founder-led company

Xencor stock price today

$7.74
-16.54
-68.14%
Financial Health
0
1
2
3
4
5
6
7
8
9

Xencor stock price monthly change

+23.24%
month

Xencor stock price quarterly change

+23.24%
quarter

Xencor stock price yearly change

+15.06%
year

Xencor key metrics

Market Cap
1.67B
Enterprise value
1.64B
P/E
-30.05
EV/Sales
11.49
EV/EBITDA
-38.35
Price/Sales
11.42
Price/Book
2.24
PEG ratio
0.18
EPS
-2.19
Revenue
162.18M
EBITDA
-129.48M
Income
-133.35M
Revenue Q/Q
-32.47%
Revenue Y/Y
65.41%
Profit margin
-38.6%
Oper. margin
-57.69%
Gross margin
21.11%
EBIT margin
-57.69%
EBITDA margin
-79.84%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Xencor stock price history

Xencor stock forecast

Xencor financial statements

Average Price Target
Last Year

$30

Potential upside: 287.59%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Xencor, Inc. (NASDAQ:XNCR): Profit margin
Jun 2023 45.52M -21.95M -48.23%
Sep 2023 59.16M -24.26M -41.02%
Dec 2023 44.68M -19.1M -42.74%
Mar 2024 12.80M -68.03M -531.3%
Xencor, Inc. (NASDAQ:XNCR): Debt to assets
Jun 2023 778121000 99.24M 12.75%
Sep 2023 778430000 109.42M 14.06%
Dec 2023 952692000 283.55M 29.76%
Mar 2024 884255000 272.06M 30.77%
Xencor, Inc. (NASDAQ:XNCR): Cash Flow
Jun 2023 -38.2M -1.40M 1.92M
Sep 2023 -27.28M 45.32M 356K
Dec 2023 181.20M -202.63M 22.98M
Mar 2024 -55.25M 32.31M 186K

Xencor alternative data

Xencor, Inc. (NASDAQ:XNCR): Employee count
Aug 2023 281
Sep 2023 281
Oct 2023 281
Nov 2023 281
Dec 2023 281
Jan 2024 281
Feb 2024 281
Mar 2024 280
Apr 2024 280
May 2024 280
Jun 2024 280
Jul 2024 280

Xencor other data

44.01% -55.99%
of XNCR is owned by hedge funds
26.25M -35.03M
shares is hold by hedge funds

Xencor, Inc. (NASDAQ:XNCR): Insider trades (number of shares)
Period Buy Sel
Feb 2024 53 54108
Mar 2024 0 47243
May 2024 0 4745
Jul 2024 0 36329
Sep 2024 0 14519
Nov 2024 0 121328
Dec 2024 0 14722
Transaction Date Insider Security Shares Price per share Total value Source
Option
MONTGOMERY ALAN BRUCE director
Common Stock 430 $20 $8,600
Option
MONTGOMERY ALAN BRUCE director
Common Stock 991 $15.35 $15,212
Sale
MONTGOMERY ALAN BRUCE director
Common Stock 1,421 $27.03 $38,407
Option
MONTGOMERY ALAN BRUCE director
Stock Option (Right to Buy) 991 $15.35 $15,212
Option
MONTGOMERY ALAN BRUCE director
Stock Option (Right to Buy) 430 $20 $8,600
Option
MONTGOMERY ALAN BRUCE director
Common Stock 5,008 $20 $100,160
Option
MONTGOMERY ALAN BRUCE director
Common Stock 8,293 $15.35 $127,298
Sale
MONTGOMERY ALAN BRUCE director
Common Stock 13,301 $27.03 $359,526
Option
MONTGOMERY ALAN BRUCE director
Stock Option (Right to Buy) 8,293 $15.35 $127,298
Option
MONTGOMERY ALAN BRUCE director
Stock Option (Right to Buy) 5,008 $20 $100,160
Patent
Application
Filling date: 17 May 2022 Issue date: 8 Sep 2022
Grant
Filling date: 13 Aug 2019 Issue date: 2 Aug 2022
Application
Filling date: 23 Dec 2021 Issue date: 21 Jul 2022
Application
Filling date: 18 Jan 2022 Issue date: 7 Jul 2022
Grant
Filling date: 11 Oct 2019 Issue date: 5 Jul 2022
Application
Filling date: 16 Mar 2022 Issue date: 30 Jun 2022
Application
Filling date: 11 Mar 2022 Issue date: 23 Jun 2022
Grant
Filling date: 8 Jun 2017 Issue date: 21 Jun 2022
Grant
Filling date: 10 Sep 2013 Issue date: 21 Jun 2022
Grant
Filling date: 3 Oct 2019 Issue date: 14 Jun 2022
Thursday, 12 December 2024
zacks.com
Wednesday, 4 December 2024
zacks.com
Tuesday, 26 November 2024
businesswire.com
Friday, 22 November 2024
seekingalpha.com
Monday, 18 November 2024
zacks.com
Thursday, 14 November 2024
zacks.com
Wednesday, 6 November 2024
zacks.com
businesswire.com
Monday, 4 November 2024
businesswire.com
Friday, 1 November 2024
zacks.com
Tuesday, 29 October 2024
zacks.com
Wednesday, 16 October 2024
zacks.com
Friday, 4 October 2024
businesswire.com
Thursday, 12 September 2024
businesswire.com
seekingalpha.com
zacks.com
Tuesday, 10 September 2024
zacks.com
Monday, 9 September 2024
businesswire.com
Monday, 5 August 2024
zacks.com
Thursday, 13 June 2024
businesswire.com
Thursday, 9 May 2024
businesswire.com
Monday, 6 May 2024
Zacks Investment Research
Thursday, 2 May 2024
Zacks Investment Research
Tuesday, 27 February 2024
Zacks Investment Research
Tuesday, 20 February 2024
Business Wire
Monday, 19 February 2024
Zacks Investment Research
Thursday, 15 February 2024
Zacks Investment Research
Tuesday, 31 October 2023
Zacks Investment Research
Friday, 27 October 2023
Seeking Alpha
Friday, 20 October 2023
Seeking Alpha
  • What's the price of Xencor stock today?

    One share of Xencor stock can currently be purchased for approximately $7.74.

  • When is Xencor's next earnings date?

    Unfortunately, Xencor's (XNCR) next earnings date is currently unknown.

  • Does Xencor pay dividends?

    No, Xencor does not pay dividends.

  • How much money does Xencor make?

    Xencor has a market capitalization of 1.67B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.28% to 168.34M US dollars.

  • What is Xencor's stock symbol?

    Xencor, Inc. is traded on the NASDAQ under the ticker symbol "XNCR".

  • What is Xencor's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Xencor?

    Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Xencor's key executives?

    Xencor's management team includes the following people:

    • Dr. Bassil I. Dahiyat Ph.D. Co-Founder, Chief Executive Officer, Pres & Director(age: 55, pay: $971,930)
    • Dr. Allen S. Yang M.D., Ph.D. Senior Vice President & Chief Medical Officer(age: 57, pay: $678,930)
    • Dr. John R. Desjarlais Senior Vice President of Research & Chief Scientific Officer(age: 61, pay: $637,930)
    • Mr. John J. Kuch Senior Vice President & Chief Financial Officer(age: 66, pay: $584,930)
    • Ms. Celia E. Eckert J.D. Vice President, Gen. Counsel & Corporation Sec.(age: 53, pay: $572,860)
  • Is Xencor founder-led company?

    Yes, Xencor is a company led by its founder Dr. Bassil I. Dahiyat Ph.D..

  • How many employees does Xencor have?

    As Jul 2024, Xencor employs 280 workers.

  • When Xencor went public?

    Xencor, Inc. is publicly traded company for more then 11 years since IPO on 3 Dec 2013.

  • What is Xencor's official website?

    The official website for Xencor is xencor.com.

  • Where are Xencor's headquarters?

    Xencor is headquartered at 111 West Lemon Avenue, Monrovia, CA.

  • How can i contact Xencor?

    Xencor's mailing address is 111 West Lemon Avenue, Monrovia, CA and company can be reached via phone at +62 630 55900.

  • What is Xencor stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Xencor in the last 12 months, the avarage price target is $30. The average price target represents a 287.59% change from the last price of $7.74.

Xencor company profile:

Xencor, Inc.

xencor.com
Exchange:

NASDAQ

Full time employees:

280

Industry:

Biotechnology

Sector:

Healthcare

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

111 West Lemon Avenue
Monrovia, CA 91016

CIK: 0001326732
ISIN: US98401F1057
CUSIP: 98401F105